Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RIDINILAZOLE (200 MG, BID) FOR 10 DAYS WITH VANCOMYCIN (125 MG, QID) FOR 10 DAYS IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION (CDI).

Intervention/treatment:
RIDINILAZOLE / VANCOMYCIN
Medical condition:
CLOSTRIDIUM DIFFICILE INFECTION
Protocol code:
SMT19969/C004
Control number:
227978
Status:
Closed
Approved:
June 13, 2019
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03595553
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Katie Tran
Organization
Summit Therapeutics
Phone:
408 677 6503
Sponsor
SUMMIT (OXFORD) LIMITED

Locations

Recherche Médicale St-Jérôme Inc
Québec, J7Z 5T3

Alberta

Foothills Medical Centre, South Tower
Calgary, Alberta, T2N 2T9

New Brunswick

Moncton Hospital/Horizon Health Network
Moncton, New Brunswick, E1C 6Z8

Ontario

Lakeridge Health
Oshawa, Ontario, L1G 2B9

Quebec

Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2X 1R9
Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec
Trois-Rivières, Quebec, G8Z 3R9
Institut Universitaire de Cardiologie et de Pneumologie de Québec- ULaval
Québec, Quebec, G1V 4G5

Results

See the results from the trial NCT03595553. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?